Compare AbbVie Inc (ABBV) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Sirius XM Holdings Inc — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while Sirius XM Holdings Inc trades at $30.27 (market cap $10.34B). The key difference: AbbVie Inc is far larger — about 43.5× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays the higher dividend (3.52%). Which is the better fit depends on your goals.
| ABBV | SIRI | |
|---|---|---|
Market Cap | $449.91B | $10.34B |
Sector | Health | Media |
52-Week High | $261.07 | $30.75 |
52-Week Low | $184.85 | $19.92 |
Enterprise Value | $513.38B | $20.01B |
Dividend Yield | 2.72% | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates solid revenue growth, reaching $61.16B in 2025, though net margins have compressed to 5.79%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $2.65 exceeding the $2.59 forecast. Positive clinical trial results for ELAHERE in ovarian cancer and institutional buying activity support investor confidence.
AbbVie presents a favorable risk-reward profile with 68% analyst buy ratings and a $266.33 consensus price target offering 5.4% upside. Key opportunities include Skyrizi/Rinvoq growth offsetting Humira declines, while risks involve patent expirations in the 2030s and margin pressure. The stock's elevated P/E of 124.83 reflects growth expectations but warrants monitoring of execution against guidance.
Sirius XM (SIRI) trades at $30.71, up 0.66% on the day, with a bullish technical signal from moving averages. The stock shows solid fundamentals with a P/E of 13.03 and a net income margin of 9.86%, supported by recent earnings beats. Analysts maintain a consensus Buy rating with a $31.17 price target, and the company continues to generate strong operating cash flow of $1.90B in 2025. Recent news highlights a new advertising partnership with Alphabet and upcoming Q2 2026 earnings.
The outlook for SIRI is positive, driven by consistent earnings performance and strategic partnerships. Key opportunities include dividend yield and potential index inclusion benefits. Risks involve high debt levels and competitive pressures in the media sector. The stock's current price near the consensus target suggests limited upside unless earnings exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
